Startups
Kasvu Therapeutics
Kasvu Therapeutics is a Helsinki biotechnology company developing small-molecule medicines for neuropsychiatric and neurodegenerative disorders. Its lead programme KTX-0141 positively modulates the TrkB receptor to enhance neuroplasticity without engaging the serotonin receptor associated with psychedelic hallucinations. Originating from University of Helsinki research, the company is conducting studies needed before human trials and plans clinical development in major depressive disorder. Its drug candidates remain investigational; reported activity and safety findings are preclinical.
Founded 2023
Team
Alan HarrisCMC Lead (Drug Substance) |
Ali LeeHead of Intellectual Property |
Georgina AskelandNon-Executive Board Member |
Georgios TrichasChief Business Officer |
Hans MoebiusScientific Advisory Board Member |
Jami MandelinCo-founder, Chief Executive Officer and Board Member |
Keith PurdyCMC Lead (Drug Product) |
Liz Mortimer-CassenToxicology Lead |
Markéta ChlubnováBoard Observer |
Matti HautsaloNon-Executive Board Member |
Matti KarvonenChief Medical Officer |
Miia KayeBoard Observer |
Pekka SimulaBoard Chair |
Pete HutsonScientific Advisory Board Member |
Peter GallagherCo-founder and Medicinal Chemistry Lead |
Rafael MolinerCo-founder and Chief Scientific Officer |
 Raymond SanchezScientific Advisory Board Member |
Sara KangaspeskaBoard Observer |
Satu JuhilaResearch Program Director |
Tim Schulz-UtermoehlDMPK Lead |